ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 341

Evaluation of 25-Hydroxyvitamin D Levels in Rheumatologic Diseases

María Lorena Brance1, Lucas Ricardo Brun1, Maria Silvia Larroude2, Mónica Patricia Sacnun3, Carolina Aeschlimann3, Guillermo Berbotto4, Ignacio Chavero1, Mariano Palatnik1 and Ariel Sánchez5, 1Centro de Reumatología., Rosario, Argentina, 2Hospital Milstein, Buenos Aires, Argentina, 3Hospital Provincial, Rosario, Argentina, 4Sanatorio Británico, Rosario, Argentina, 5Centro de Endrocrinología., Rosario, Argentina

Meeting: 2016 ACR/ARHP Annual Meeting

Date of first publication: September 28, 2016

Keywords: Vitamin D and rheumatologic disease

  • Tweet
  • Email
  • Print
Session Information

Date: Sunday, November 13, 2016

Title: Osteoporosis and Metabolic Bone Disease – Clinical Aspects and Pathogenesis - Poster

Session Type: ACR Poster Session A

Session Time: 9:00AM-11:00AM

Background/Purpose:  Previous evidence indicates an association between vitamin D deficiency and autoimmune diseases. The aim of this study was to evaluate serum 25 hydroxyvitamin D (25OHD) and bone mineral density (BMD) in patients with rheumatologic diseases (RD) in Argentinean patients. In addition, 25OHD levels were analyzed in function of disease activity.

Methods:  This retrospective study evaluated 106 patients with RD (64 with rheumatoid arthritis (RA), 12 spondyloarthropathies (SA), 13 systemic lupus erythematosus (SLE) and 17 other collagenopathies (OC) [vasculitis, scleroderma, indiferenciateted disease connective tissue, superposition syndrome of connective tissue disease]) and was compared with a control group (CG, n=102) matched by age (CG= 55.82±1.48 years; RD= 55.28±1.30, sex and body mass index. All the patients were from Rosario (32º52´18´´S) and Buenos Aires (34º36´14´´S) cities. Exclusion criteria: supplemented with vitamin D, pregnancy, intestinal malabsorption, chronic liver or kidney disease or cancer. Date are expressed as mean±SEM. Differences between groups were analyzed using the Mann–Whitney or Kruskal–Wallis test. Correlations were performed with Spearman’s correlation test. The difference was considered significant if p<0.05.

Results:  No differences between groups were observed in serum calcium, phosphatemia, urinary calcium, parathormone and urinary deoxipiridinoline. Significant differences were found in alkaline phosphatase (CG= 102.90±5.40 UI/l; RD= 167.2±8.59) and 25OHD (CG= 25.64±1.06 ng/ml; RD= 19.17±0.66). 25OHD significantly correlated with erythrocyte sedimentation rate (ERS) [r= -0.26] and reactive C-protein (RCP) [r = -0.27] as acute phase reactants. RD patients had significant lower 25OHD levels (RA= 19.89±0.81; SA=15.64±1.76; SLE= 19.81±2.49; and OC= 18.44±1.48) than CG (25.64±1.06 ng/ml). No correlation between 25OHD levels and DAS-28 and HAQ-DI scores were found. However, lower values of 25OHD were found at higher scores: HAQ-20 ≤2= 22.41±1.45 ng/ml, HAQ-20 >2= 18.80±0.95, p=0.047; DAS28 ≤3.2= 21.43±1.62 ng/ml, DAS28 >3.2= 19.78±0.95l, p=0.157. Activity scores in others RD couldn´t be analyzed because small number of patients. No significant differences were found in lumbar spine BMD between premenopausal or postmenopausal (postM) patients, but femoral neck BMD was significantly lower in postM RD patients (0.775±0.026 g/cm2; T-score −1.94±0.20) than in postM CG patients (0.802±0.020; T-score −1.24±0.16).

Conclusion:  In both groups 25OHD levels were under 30 ng/ml. However, 25OHD levels were lower in RD patients (deficiency) than CG (insufficiency). Lower values of 25OHD were found at higher ERS and RCP in all RD and at higher activity disease scores in RA.


Disclosure: M. L. Brance, None; L. R. Brun, None; M. S. Larroude, None; M. P. Sacnun, None; C. Aeschlimann, None; G. Berbotto, None; I. Chavero, None; M. Palatnik, None; A. Sánchez, None.

To cite this abstract in AMA style:

Brance ML, Brun LR, Larroude MS, Sacnun MP, Aeschlimann C, Berbotto G, Chavero I, Palatnik M, Sánchez A. Evaluation of 25-Hydroxyvitamin D Levels in Rheumatologic Diseases [abstract]. Arthritis Rheumatol. 2016; 68 (suppl 10). https://acrabstracts.org/abstract/evaluation-of-25-hydroxyvitamin-d-levels-in-rheumatologic-diseases/. Accessed .
  • Tweet
  • Email
  • Print

« Back to 2016 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/evaluation-of-25-hydroxyvitamin-d-levels-in-rheumatologic-diseases/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology